Back to Search
Start Over
Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacteralesin the Antibiotic Resistance Laboratory Network, March 2019 to December 2020
- Source :
- Antimicrobial Agents and Chemotherapy; July 2021, Vol. 65 Issue: 8
- Publication Year :
- 2021
-
Abstract
- Aztreonam-avibactam is a drug combination pending phase 3 clinical trials and is suggested for treatment of severe infections caused by metallo-beta-lactamase (MBL)-producing Enterobacteralesby combining ceftazidime-avibactam and aztreonam. Beginning in 2019, four Antibiotic Resistance Laboratory Network regional laboratories offered aztreonam-avibactam susceptibility testing by broth microdilution.
Details
- Language :
- English
- ISSN :
- 00664804 and 10986596
- Volume :
- 65
- Issue :
- 8
- Database :
- Supplemental Index
- Journal :
- Antimicrobial Agents and Chemotherapy
- Publication Type :
- Periodical
- Accession number :
- ejs57064053
- Full Text :
- https://doi.org/10.1128/AAC.00486-21